Search Results
Your search for The ASCO matches 21099 pages
Showing 12301 - 12350FDA Accepts sNDA for Lenvatinib for the Treatment of Hepatocellular Carcinoma
On September 26, Eisai Inc announced the U.S. Food and Drug Administration (FDA) has accepted for review a supplemental New Drug Application (sNDA) for lenvatinib (Lenvima) for potential use in the first-line treatment of patients with hepatocellular carcinoma. “Patients with...
MSLT-II Completion Lymph Node Dissection Trial: Practice Changing but Not Likely Practice Abandoning
PROBABLY THE MOST IMPORTANT advance in the treatment of newly diagnosed primary melanoma has been the incorporation of sentinel lymph node biopsy as part of initial surgical management. The routine use of sentinel lymph node biopsy, often termed “sentinel lymphadenectomy,” in appropriately...
Abemaciclib Plus Endocrine Therapy Extends Progression-Free Survival in First-Line Therapy for Advanced Breast Cancer
THE VALUE OF cyclin-dependent kinase 4/6 (CDK4/6) inhibitors in advanced breast cancer became ever more certain with the announcement of interim data from MONARCH 3, which evaluated abemaciclib in combination with endocrine therapy as first-line therapy for hormone receptor–positive/HER2-negative...
Study Finds 'Standard Care' Treatments in Breast Cancer Clinical Trials Not Always Standard
Historically, randomized controlled trials have served as the state-of-the-art method for determining the efficacy and safety of new, innovative treatment regimens for patients with cancer and other diseases. It is imperative that such trials are carefully designed to ensure that they are...
European Commission Approves Obinutuzumab for Previously Untreated Advanced Follicular Lymphoma
On September 22, Roche announced that the European Commission has approved obinutuzumab (Gazyvaro in Europe; available in the United States as Gazyva) in combination with chemotherapy, followed by obinutuzumab maintenance in patients achieving a response, as a new treatment for previously untreated ...
Lymphoma Physician-Scientist Oliver Press, MD, PhD, Dies at 65
Oliver Press, MD, PhD, a blood cancer physician-scientist who made foundational contributions to the development of targeted cancer therapies, died Friday of complications from glioma. He was 65 years old. Dr. Press was the David and Patricia Giuliani/Oliver Press Endowed Chair for Cancer Research ...
FDA Conducts Global Operation to Protect Consumers From Potentially Dangerous Prescription Drugs Sold Online
The U.S. Food and Drug Administration (FDA), in partnership with international regulatory and law enforcement agencies, recently took action against more than 500 websites that illegally sell potentially dangerous, unapproved versions of prescription medicines, including opioids, antibiotics, and...
FDA Grants Priority Review for Pertuzumab for Adjuvant Treatment of HER2-Positive Early Breast Cancer
On September 29, Roche announced the U.S. Food and Drug Administration (FDA) has accepted the company’s supplemental Biologics License Application and granted Priority Review for pertuzumab (Perjeta), in combination with trastuzumab (Herceptin) and chemotherapy, for adjuvant treatment of...
What Is the Most Important Factor Women Consider in Deciding on SERM Use to Reduce Their Risk of Breast Cancer?
Currently, two medications have been approved by the U.S. Food and Drug Administration to reduce the risk of breast cancer: tamoxifen and raloxifene. Both medications, selective estrogen receptor modulators (SERMs), have been shown to reduce the risk for breast cancer by up to 50% in prevention...
Biden Cancer Initiative: Accelerating Progress in Cancer Research
Earlier this year, at the Alexandria Center for Life Science, former Vice President Joe Biden and Jill Biden, PhD, launched the Biden Cancer Initiative, their new venture to continue the fight to make progress in cancer prevention, detection, treatment, and care. The Biden Cancer Initiative will...
ASTRO 2017: Shorter Course of Radiation Treatment Safe for Breast Cancer Patients Under 50
A higher-dose, shorter form of radiation is safe, effective, and no more damaging to the breast tissue or skin of breast cancer patients under age 50 than it is in older patients. This is the finding of a study led by researchers from Perlmutter Cancer Center at New York University (NYU)...
Molecular Profiling of Key Survival Proteins in B-Cell Lymphoma Subtypes
Investigators at the Sidney Kimmel Cancer Center at Jefferson uncovered potential new proteins that contribute to the development and progression of several types of lymphoma. Their findings were published by Adams et al in Clinical Cancer Research. The researchers focused their attention on...
Nivolumab Approved in Japan for Unresectable Advanced or Recurrent Gastric Cancer That Has Progressed After Chemotherapy
On September 22, Bristol-Myers Squibb Company announced that the Japanese Ministry of Health, Labor and Welfare (MHLW) approved nivolumab (Opdivo) for the treatment of unresectable advanced or recurrent gastric cancer which has progressed after chemotherapy. This approval was based on the phase III ...
Shorter Course of Radiation Therapy Safe for Younger Women With Breast Cancer
A higher-dose, shorter form of radiation is safe, effective, and no more damaging to the breast tissue or skin of women with breast cancer under age 50 than it is in older patients, according to findings led by researchers from Perlmutter Cancer Center at NYU Langone Health, and presented at the...
Cancer Has Plagued My Family
My father, who was a physician, taught me at an early age to pay attention to any changes in my body. His advice has stood me in good stead for more than 83 years and probably saved my life more than once. In 1984, just before I turned 50, something was bothering me about my right breast. I could...
Epithelioma Tubule De Nez, Albumen Print Paris, 1872
The text and photograph on this page are excerpted from a four-volume series of books titled Oncology Tumors & Treatment: A Photographic History, by Stanley B. Burns, MD, FACS, and Elizabeth A. Burns. The photo below is from the volume titled “The Anesthesia Era: 1845–1875.” The photograph...
FDA Grants Accelerated Approval to Pembrolizumab for Advanced Gastric Cancer
On September 22, 2017, the U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab (Keytruda) for patients with recurrent locally advanced or metastatic, gastric or gastroesophageal junction adenocarcinoma whose tumors express programmed cell death ligand 1 (PD-L1) as ...
Current Oncology Landscape
ASCO released a landmark strategic plan to guide future efforts for increasing racial and ethnic diversity in the oncology workforce. The ultimate goal is to develop a workforce that provides high-quality cancer care to racial and ethnic populations who experience persistent disparities in access...
Increasing Racial and Ethnic Diversity in the Oncology Workforce
Although significant progress has been made in cancer incidence and mortality in the United States over the past 2 decades—the death rate fell 23% between 1991 and 20121—not everyone is benefiting equally. According to the American Cancer Society, blacks have the highest death rate and shortest...
National Committee for Quality Assurance Recognizes Sidney Kimmel Cancer Center at Jefferson
The Sidney Kimmel Cancer Center of the Thomas Jefferson University in Philadelphia has announced the receipt of two accolades by the National Committee for Quality Assurance (NCQA). Jefferson Oncology Medical Associates has been recognized by the NCQA for patient-centered specialty practice (PCSP)...
Endocrine Society Names V. Craig Jordan, OBE, PhD, 2018 Laureate
V. Craig Jordan, OBE, PhD, has been recognized by the Endocrine Society as the 2018 Laureate of the Gerald D. Aurbach Award for Outstanding Translational Research. Dr. Jordan is the Dallas/Fort Worth Living Legend Chair of Cancer Research in the Department of Breast Medical Oncology at The...
Adjuvant Pertuzumab in HER2-Positive Breast Cancer: Value Yet to Be Demonstrated
The ASCO Post issue of June 25, 2017, did an excellent job of summarizing the results and controversy generated by the initial results of the APHINITY trial, reported at the 2017 ASCO Annual Meeting and published simultaneously online in The New England Journal of Medicine.1 With a median follow-up ...
With Financial Toxicity in Oncology Care on the Rise, Providers Need to Help Address Patients’ Financial Issues
At the 2017 ASCO Quality Care Symposium, Dan Sherman, MA, LPC, discussed potential solutions to the persistent challenge of financial toxicity in the oncology setting. Mr. Sherman is a clinical financial consultant and Founder and President of The Navectis Group, Caledonia, Michigan. Rather than...
Anthony Back, MD, to Receive Inaugural Walther Cancer Foundation Award
ASCO will honor Anthony Back, MD, with its inaugural Walther Cancer Foundation Palliative and Supportive Care in Oncology Endowed Award and Lecture. Endowed by the Walther Cancer Foundation,* this award and lecture was established to recognize a distinguished lecturer and leader with multiple,...
Recognizing the Importance of a Work-Life Balance in Oncology
The ASCO Post introduces this new department, Living a Full Life, in which we will share insightful narratives of oncology professionals highlighting personal aspects of these clinicians’ lives separate from the world of oncology. We also intend to open a dialogue about the challenges that today’s...
Cancer Policy Priorities Front and Center on Capitol Hill
On September 27 and 28, more than 100 ASCO volunteers headed to Capitol Hill to participate in the 2nd Annual ASCO Advocacy Summit. During the Summit, advocates met with members of Congress and staff to educate them on critical issues affecting patients and providers and to encourage policymakers...
Obtaining a Second Graduate Degree During Fellowship: Things to Consider
KAH POH (MELISSA) LOH, MBBCh BAO Institution: Fellow, University of Rochester Medical CenterMember since: 2013ASCO activities: Trainee Council Hematology and oncology fellowship training requires at least 3 years to complete. For fellows who wish to single board in either hematology or oncology, a ...
ASCO and Friends of Cancer Research Release Comprehensive Recommendations to Broaden Eligibility Criteria for Cancer Clinical Trials
ASCO and Friends of Cancer Research (Friends) are calling for the use of more inclusive eligibility criteria for cancer clinical trials in a new Special Series in the Journal of Clinical Oncology (JCO). The series provides a comprehensive examination of eligibility criteria for cancer clinical...
ASCO Concerned With MIPS Part B Reimbursement Assessments in QPP Proposal
ASCO submitted comments to the Centers for Medicare & Medicaid Services (CMS) on its proposed rule outlining changes to the Quality Payment Program (QPP) for 2018. In a letter to CMS Administrator Seema Verma, ASCO President Bruce E. Johnson, MD, FASCO, made recommendations regarding the two...
ASCO’s QOPI Certification Program™ Recognizes Three Oncology Practices in Spain
ASCO has announced that the first three practices in Spain have received Quality Oncology Practice Initiative (QOPI®) certification through the QOPI Certification Program™, LLC (QCP). The accreditations were given on September 8, at the European Society for Medical Oncology (ESMO) 2017 Congress in...
Educate and Support Your Patients With ASCO Answers Materials
Provide your patients with ASCO-approved information on cancer. ASCO Answers materials are available as fact sheets and booklets, covering many types of cancer as well as treatments and side effects. Order printed copies online today through the ASCO Bookstore at www.cancer.net/estore. Enjoy free ...
Spotlight on Women Who Conquer Cancer
Women Who Conquer Cancer is a group dedicated to advancing cancer research by supporting young female researchers early in their careers through Conquer Cancer Foundation (CCF) Young Investigator Awards (YIAs). These 1-year grants give promising researchers the boost they need to get started on...
CCF Researcher Spotlight: Rizwan Romee, MD
RIZWAN ROMEE, MD Assistant Professor of Medicine & Clinical Director, Haploidentical Transplant Program Washington University in St. Louis St. Louis, Missouri Acute myeloid leukemia, or AML, is the most common type of acute blood cancer in the adult population and can be very difficult to...
FDA Expands Approval of Ipilimumab to Pediatric Patients 12 Years and Older
On July 24, the U.S. Food and Drug Administration (FDA) expanded the indication for ipilimumab (Yervoy) injection for intravenous use now to include the treatment of unresectable or metastatic melanoma in pediatric patients 12 years of age and older. Ipilimumab was evaluated in 2 trials of...
ASTRO 2017: Uninsured Patients With Cancer Saw Increased Coverage for Care Following Medicaid Expansion
A new study found that Medicaid expansion enacted as part of the Patient Protection and Affordable Care Act (ACA) improved coverage for care for patients with cancer receiving radiation therapy and potentially decreased health-care disparities. Analysis of more than 197,000 patient records from one ...
ASTRO 2017: Accelerated Breast Radiation Therapy Following Mastectomy Can Shorten Treatment Time While Maintaining Tumor Control
Radiation therapy following mastectomy for intermediate-stage, high-risk breast cancer can be shortened from 5 to 3 weeks while maintaining tumor control rates in the breast and surrounding region that are equivalent to conventional treatment, according to research presented by Sun et al at the...
William A. Hall, MD, on Prostate Cancer: Results From a Study of Three Treatment Modalities
William A. Hall, MD, of the Medical College of Wisconsin, discusses trial findings on androgen deprivation and radiation alone, compared with androgen deprivation, radiotherapy, and surgery in men with high-risk, nonmetastatic adenocarcinoma of the prostate (Abstract 15).
Christopher R. Kelsey, MD, on DLBCL: Study Results on Consolidation Radiotherapy
Christopher R. Kelsey, MD, of Duke University Medical Center, discusses reducing the radiation dose from 30 Gy to 20 Gy for patients with diffuse large B-cell lymphoma. Phase II findings show this approach may be effective in light of improved systemic treatment and better chemotherapy response...
Gerard Morton, MD, on GU Highlights: Expert Perspective
Gerard Morton, MD, of Sunnybrook Odette Cancer Centre, summarizes a session that included discussion of late toxicities of radiotherapy for locally recurrent prostate cancer; using chemotherapy instead of radiation in early-stage seminoma; radiotherapy vs surgery plus radiotherapy in Gleason score...
Shrinivas Rathod, MD, on NSCLC: Quality-of-Life Outcomes From an IAEA Trial
Shrinivas Rathod, MD, of the University of Manitoba, discusses phase III study results on optimization of treatment of advanced non–small cell lung cancer using radiation therapy and chemotherapy (Abstract 223).
Bhishamjit S. Chera, MD, on Oropharyngeal Squamous Cell Carcinoma and HPV-16: Expert Perspective
Bhishamjit S. Chera, MD, of the University of North Carolina, discusses quantification of human papillomavirus 16 in circulating tumor DNA during de-intensified chemoradiation therapy for favorable-risk HPV-associated oropharyngeal squamous cell carcinoma (Presentation 92).
ASTRO 2017: Patients With Breast Cancer Find Radiation Therapy Experience Better Than Expected
A new survey finds breast cancer patients’ actual radiation therapy experiences largely exceeded their expectations. The survey, which addressed the fears and misconceptions regarding radiation therapy for breast cancer, found that more than three-fourths of the breast cancer patients...
ASTRO 2017: Aggressively Reduced Radiation Therapy May Benefit Some Patients With HPV-Related Throat Cancer
For certain patients with oropharyngeal cancer caused by the human papillomavirus (HPV), an aggressive reduction of radiation therapy after surgery may provide cancer control while simultaneously reducing post-treatment side effects, improving quality of life, and lowering treatment costs,...
ASTRO 2017: GOG-249 Confirms Adjuvant Pelvic Radiation as Standard of Care for High-Risk, Early-Stage Endometrial Cancer
In a new phase III trial report from the National Clinical Trial Network group, NRG Oncology, recurrence-free and overall survival rates for women with stage I–II high-risk endometrial cancer were not superior following adjuvant vaginal cuff brachytherapy plus chemotherapy when compared with...
Second Annual ASCO Advocacy Summit Convenes in Washington, DC
Nearly 100 oncology care providers from across the United States traveled to Capitol Hill on September 27 and 28 to participate in the second annual ASCO Advocacy Summit. Advocates met with Members of Congress and their staff to educate them on critical issues affecting patients with cancer ...
FDA Approves New CDK4/6 Inhibitor for Certain Advanced or Metastatic Breast Cancers
The U.S. Food and Drug Administration today approved abemaciclib (Verzenio) to treat adult patients who have hormone receptor–positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer that has progressed after endocrine therapy. Abemaciclib is...
Shulian Wang, MD, and Benjamin Movsas, MD, on Breast Cancer: Radiation Therapy After Mastectomy
Shulian Wang, MD, of the National Cancer Center in Beijing, and Benjamin Movsas, MD, of the Henry Ford Health System, discuss study results on the use of hypofractionated radiation therapy after mastectomy for the treatment of high-risk breast cancer (Abstract PL01).
Tamim Niazi, MDCM, on Prostate Cancer: Results From a Trial on Dose Escalation
Tamim Niazi, MDCM, of McGill University, discusses phase III study findings on hypofractionated, dose-escalation radiation therapy for high-risk adenocarcinoma of the prostate (Abstract 281).
Maria Werner-Wasik, MD, on Lung Cancer Highlights: Expert Perspective
Maria Werner-Wasik, MD, of Thomas Jefferson University Hospital, summarizes a session on NSCLC that included discussion of a quality-of-life trial on optimizing treatment; chemotherapy and radiotherapy in advanced disease; a comparison of standard- vs high-dose conformal chemoradiotherapy; and...
